Simian Vaccine Evaluation Units 2013-2020

The National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID) awarded a Master IDIQ on May 1, 2013 for nonhuman primate resources and support services for preclinical evaluation of AIDS vaccines and related prevention modalities. Ordering closed on April 30, 2020, and is no longer available for new task orders.

The vehicle is fully expired and unsuitable for pursuit. No new orders have been accepted for more than six years. The vehicle established on May 1, 2013 executed 46 task orders before its ordering period closed. Combined potential value across all task orders reached $81.9 million, with $68.2 million obligated (83% burn). Activity peaked in 2016 with six orders, then declined to two orders in 2018 before stabilizing at three orders annually in 2019 and 2020, signaling a wind-down rather than sustained demand.

Three primes captured the entire portfolio. Advanced Bioscience Laboratories, Inc. holds the dominant position with 22 orders valued at $43.1 million combined potential—roughly 53% of total vehicle value. The Administrators Of Tulane Educational Fund follows with nine orders at $23.2 million (28%), and Bioqual, Inc. holds 15 orders at $15.6 million (19%). All task orders are unrestricted (no set-aside designation).

Ninety-eight percent of all task orders fund NIAID/DAIDS directly (45 of 46 orders at $80.5 million combined potential value); one order valued at $1.4 million funded NIAID DEA OA Acquisitions. Task orders reflect maintenance and breeding of nonhuman primate colonies, individual preclinical vaccine studies (Study P172, P186, P191, P195, P197, P204, P205, P208, P209, P210), and transition activities. Most awards use Cost Plus Fixed Fee pricing; some use Cost No Fee. Task-order values span from under $150,000 to over $15 million, with durations typically two to four years.

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, Division of AIDS (DAIDS) has awarded a Master IDIQ for the provision of support services for the NIAID/DAIDS clinical research portfolio.The development of HIV vaccines and other prevention strategies relies on the use of nonhuman primates in preclinical studies to advance the development of effective AIDS vaccine candidates and to advance development of effective topical microbicides and other prevention modalities or immune-based therapies. The NIAID Simian Vaccine Evaluation Unit (SVEU) contracts provide nonhuman primate resources that primarily support preclinical evaluation of AIDS vaccines.